Efficacy and safety of rebamipide tablets combined with rabeprazole sodium enteric-coated tablets in the treatment of chronic atrophic gastritis

Abstract

Objective To analyze the efficacy and safety of rebamipide tablets combined with rabeprazole sodium enteric-coated tablets in the treatment of chronic atrophic gastritis (CAG). Methods A total of 192 CAG patients admitted to Central Hospital of Henan Energy Jiaozuo Coal Industry Group from January 2013 to January 2018 were included and randomly divided into control group and observation group according to the ratio of 1∶1, with 96 cases in each group. Control group was treated with rabeprazole sodium enteric-coated tablets, and observation group was given rebamipide tablets + rabeprazole sodium enteric-coated tablets, and they were treated for 4 weeks. The clinical efficacy, pathological scores (gland atrophy, intestinal metaplasia, dysplasia), gastric function-related indicators, including gastrin-17 (GAS-17), pepsinogen I (PGI), epidermal growth factor (EGF), endothelin-1 (ET-1), Hp eradication rate and safety were compared between the two groups. Results After treatment, the total improvement rate of treatment and negative conversion rate of Hp in observation group were significantly higher than those in control group, (91.67% and 80.21%) vs. (78.12% and 62.50%), the difference was statistically significant (P 0.05), with good safety. Conclusions Rebamipide tablets combined with rabeprazole sodium enteric-coated tablets has obvious effects on CAG, and it can effectively alleviate the clinical symptoms of patients and regulate the levels of gastric function-related indicators, with good safety. Key words: Rebamipide tablets; Rabeprazole sodium enteric-coated tablets; Chronic atrophic gastritis